Day: December 31, 2019

SANTA CLARA, Calif., Dec. 31, 2019 (GLOBE NEWSWIRE) — AMD (NASDAQ: AMD) today announced that it will hold a press conference as a part of the official CES 2020 Media Days, and hosted by AMD President and CEO Dr. Lisa Su. The event is scheduled for Monday, Jan. 6 at 2:00 p.m. PST at the Mandalay Bay.A live stream of the event will be available on the AMD YouTube channel. An archived version of the webcast will be available approximately two hours after the event and can be found on the AMD YouTube channel.About AMDFor 50 years AMD has driven innovation in high-performance computing, graphics and visualization technologies ― the building blocks for gaming, immersive platforms and the data center. Hundreds of millions of consumers, leading Fortune 500 businesses and cutting-edge scientific research facilities around the world...

BEIJING, Dec. 31, 2019 (GLOBE NEWSWIRE) — Jumei International Holding Limited (NYSE: JMEI) (“Jumei” or the “Company”), China’s leading online retailer of beauty products, today announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) to its Class A ordinary shares (the “ADS Ratio”), par value US$0.00025 per share, from the current ADS Ratio of one (1) ADS to one (1) Class A ordinary shares to a new ADS Ratio of one (1) ADS to ten (10) Class A ordinary shares. The Company anticipates that the change in the ADS Ratio will be effective on or about January 10, 2020 (the “Effective Date”).For Jumei’s ADS holders, the change in the ADS Ratio will have the same effect as a one-for-ten reverse ADS split. On Effective Date, ADS holders of...

CALGARY, Alberta, Dec. 31, 2019 (GLOBE NEWSWIRE) — Paleo Resources, Inc. (“Paleo” or the “Corporation”) (TSX-V: PRE, OTC: PRIEF) announces that testing operations for the Dorn Prospect well have concluded. The Dorn Prospect well produced non-commercial quantities of gas and water from multiple prospective sandstone sections, and Paleo has decided to plug and abandon the well as a dry hole.Neither the TSX Venture Exchange nor its Regulation Services Provider (as the term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Paleo Resources Inc. is an oil and natural gas and mineral exploration company headquartered in Calgary, Alberta, with executive offices in Houston, Texas. The Corporation’s common shares are listed on the TSX Venture...

TORRANCE, Calif., Dec. 31, 2019 (GLOBE NEWSWIRE) — Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today reported that it received the initial purchase order relating to taiba Healthcare’s early access program for Endari® (L-glutamine oral powder) in Oman. Based in the Sultanate of Oman, taiba is a leading healthcare marketing, distribution and retail pharmacy group focused on the Gulf Cooperation Countries (Saudi Arabia, Kuwait, the United Arab Emirates, Bahrain and Oman). This region represents a large market for Endari, with Saudi Arabia alone having more patients afflicted with sickle cell disease than in the United States.Dr. Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer of Emmaus commented, “we are very pleased to have received this initial purchase...

HOUSTON, Dec. 31, 2019 (GLOBE NEWSWIRE) — Carriage Services, Inc. (NYSE:CSV) (“Carriage Services” or the “Company”) today announced that it closed the acquisition of Fairfax Memorial Park and Funeral Home in Fairfax, Virginia (collectively “Fairfax”).  Fairfax currently performs approximately 850 cemetery interments and 900 funerals annually and has combined revenue that represents the largest single business acquired in the history of the Company. About Carriage ServicesCarriage Services is a leading provider of deathcare services and merchandise in the United States. Carriage operates 188 funeral homes in 29 states and 31 cemeteries in 11 states.Certain statements made herein or elsewhere by, or on behalf of, the Company that are not historical facts are intended to be forward-looking...

VANCOUVER, British Columbia, Dec. 31, 2019 (GLOBE NEWSWIRE) — Fancamp Exploration Limited (“Fancamp” or the “Company”) (TSXV: FNC) is pleased to announce that the Company has completed the closing of a first tranche in connection with its previously announced (Fancamp News Release dated December 27, 2019) non-brokered private placement financing of up to 5,791,000 flow-through shares of the Company for gross proceeds of up to Cdn$450,000.At closing of the first tranche of the private placement, the Company issued 3,125,000 flow-through shares for gross proceeds of $250,000 (the “First Tranche”). Each flow-through share issued in connection with the First Tranche is subject to a four-month hold period under applicable securities laws in Canada, which hold period shall end on May 1st, 2020.The Company...

HALIFAX, Nova Scotia, Dec. 31, 2019 (GLOBE NEWSWIRE) — N.W. Fulcher Limited (“Fulcher”) announces that it has acquired ownership of unsecured convertible debentures in the aggregate principal amount of $1,000,000 (the “Debentures”) of Nova Leap Health Corp. (TSXV: NLH) (“Nova Leap”), with its head office at 5003-7071 Bayers Road, Halifax, Nova Scotia, B3L 2C2. Fulcher is owned and controlled by Wayne Fulcher. The Debentures are convertible into common shares of Nova Leap at a conversion price of $0.52 per common share at any time until the date that is five (5) years after the issue date. The Debentures bear interest at the rate of 8.0% per annum, payable semi-annually.The Debentures were purchased by way of a private placement and were acquired for investment purposes. Fulcher may, from time to...

AUSTIN, Texas, Dec. 31, 2019 (GLOBE NEWSWIRE) — XBiotech Inc. (NASDAQ: XBIT) hat heute den Abschluss des Verkaufs des vom Unternehmen entwickelten True Human-Antikörpers Bermekimab an Janssen Biotech, Inc. (Janssen), Teil der Janssen Pharmaceutical Companies of Johnson & Johnson, bekanntgegeben. Nach Abschluss der Transaktion zahlte Janssen 750 Mio. USD an XBiotech, wobei 75 Mio. USD für 18 Monate treuhänderisch gehalten werden. Sollte Janssen Anwendungsbereiche für Bermekimab über den Bereich der Dermatologie hinaus erforschen, könnte XBiotech nach Abschluss bestimmter Genehmigungen für die Vermarktung zusätzliche Zahlungen in Höhe von bis zu 600 Mio. USD erhalten. Neben dem Erwerb von Bermekimab haben Janssen und XBiotech Vereinbarungen über die Fertigungsversorgung und klinische...

AUSTIN, Texas, 31 déc. 2019 (GLOBE NEWSWIRE) — XBiotech Inc. (NASDAQ : XBIT) a annoncé aujourd’hui la finalisation de la vente du bermekimab, anticorps True Human de la Société, à Janssen Biotech, Inc. (Janssen), compagnie pharmaceutique Janssen de Johnson & Johnson. À la finalisation de la vente, Janssen a payé 750 millions USD à XBiotech, avec entiercement de 75 millions USD pendant 18 mois.  Si Janssen poursuit des indications de bermekimab en dehors du domaine de la dermatologie, XBiotech pourrait également recevoir jusqu’à 600 millions USD de paiements additionnels une fois certaines autorisations de commercialisation obtenues. Outre l’acquisition du bermekimab, Janssen et XBiotech ont conclu des accords...

LANCASTER, N.Y., Dec. 31, 2019 (GLOBE NEWSWIRE) — Ecology and Environment Inc. (“E & E”) (Nasdaq: EEI) today announced the completion of its previously reported acquisition by WSP Global Inc. (“WSP”). WSP is one of the world’s leading professional services firms, providing technical expertise and strategic advice to clients in the transportation and infrastructure, property and buildings, environment, industry, resources and energy sectors, as well as offering project and program delivery and advisory services. The acquisition of E & E will allow WSP to scale and strengthen its environmental capabilities.The purchase price payable for each share of E & E’s Class A and Class B common stock in connection with the acquisition is $15.00 per share, plus a special dividend of $0.50 per share...